Comparison of Commercial Dosimetric Software Platforms in Patients Treated with Lu-DOTATATE for Peptide Receptor Radionuclide Therapy

Overview

Journal Med Phys

Specialty Biophysics

Date 2020 Jul 8

PMID 32632928

Citations 20

Authors

Erick Mora-Ramirez

Lore Santoro

Emmanuelle Cassol

Juan C Ocampo-Ramos

Naomi Clayton

Gunjan Kayal

Soufiane Chouaf

Dorian Trauchessec

Jean-Pierre Pouget

Pierre-Olivier Kotzki

Emmanuel Deshayes

Manuel Bardies

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study was to quantitatively compare five commercial dosimetric software platforms based on the analysis of clinical datasets of patients who benefited from peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE (LUTATHERA ).

Methods: The dosimetric analysis was performed on two patients during two cycles of PRRT with Lu. Single photon emission computed tomography/computed tomography images were acquired at 4, 24, 72, and 192 h post injection. Reconstructed images were generated using Dosimetry Toolkit (DTK) from Xeleris™ and HybridRecon-Oncology version_1.3_Dicom (HROD) from HERMES. Reconstructed images using DTK were analyzed using the same software to calculate time-integrated activity coefficients (TIAC), and mean absorbed doses were estimated using OLINDA/EXM V1.0 with mass correction. Reconstructed images from HROD were uploaded into PLANET® OncoDose from DOSIsoft, STRATOS from Phillips, Hybrid Dosimetry Module™ from HERMES, and SurePlan™ MRT from MIM. Organ masses, TIACs, and mean absorbed doses were calculated from each application using their recommendations.

Results: The majority of organ mass estimates varied by <9.5% between all platforms. The highest variability for TIAC results between platforms was seen for the kidneys (28.2%) for the two patients and the two treatment cycles. Relative standard deviations in mean absorbed doses were slightly higher compared with those observed for TIAC, but remained of the same order of magnitude between all platforms.

Conclusions: When applying a similar processing approach, results obtained were of the same order of magnitude regardless of the platforms used. However, the comparison of the performances of currently available platforms is still difficult as they do not all address the same parts of the dosimetric analysis workflow. In addition, the way in which data are handled in each part of the chain from data acquisition to absorbed doses may be different, which complicates the comparison exercise. Therefore, the dissemination of commercial solutions for absorbed dose calculation calls for the development of tools and standards allowing for the comparison of the performances between dosimetric software platforms.

Citing Articles

MIRD Pamphlet No. 30: MIRDfit-A Tool for Fitting of Biodistribution Time-Activity Data for Internal Dosimetry.

Carter L, Ocampo Ramos J, Schuerrle S, Marquis H, Lassmann M, Bolch W J Nucl Med. 2024; 65(11):1808-1814.

PMID: 39327016 PMC: 11533917. DOI: 10.2967/jnumed.124.268011.

A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?.

Vergnaud L, Dewaraja Y, Giraudet A, Badel J, Sarrut D EJNMMI Phys. 2024; 11(1):65.

PMID: 39023648 PMC: 11554969. DOI: 10.1186/s40658-024-00658-8.

An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 3: Contribution from Calculating Absorbed Dose from Time-Integrated Activity.

Brosch-Lenz J, Kurkowska S, Frey E, Dewaraja Y, Sunderland J, Uribe C J Nucl Med. 2024; 65(8):1166-1172.

PMID: 38960715 PMC: 11294060. DOI: 10.2967/jnumed.123.267293.

Dosimetry of [Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis.

Ells Z, Grogan T, Czernin J, Dahlbom M, Calais J J Nucl Med. 2024; 65(8):1264-1271.

PMID: 38960712 PMC: 11294071. DOI: 10.2967/jnumed.124.267452.

Automated segmentation of lesions and organs at risk on [Ga]Ga-PSMA-11 PET/CT images using self-supervised learning with Swin UNETR.

Yazdani E, Karamzadeh-Ziarati N, Cheshmi S, Sadeghi M, Geramifar P, Vosoughi H Cancer Imaging. 2024; 24(1):30.

PMID: 38424612 PMC: 10903052. DOI: 10.1186/s40644-024-00675-x.

References

Johnson T, McClure D, McCourt S . MABDOSE. I: Characterization of a general purpose dose estimation code. Med Phys. 1999; 26(7):1389-95. DOI: 10.1118/1.598636. View

Hippelainen E, Tenhunen M, Maenpaa H, Sohlberg A . Quantitative accuracy of (177)Lu SPECT reconstruction using different compensation methods: phantom and patient studies. EJNMMI Res. 2016; 6(1):16. PMC: 4759452. DOI: 10.1186/s13550-016-0172-0. View

Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G . Dosimetry in Peptide radionuclide receptor therapy: a review. J Nucl Med. 2006; 47(9):1467-75. View

Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana C, Bartolomei M . Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008; 35(10):1847-56. DOI: 10.1007/s00259-008-0778-1. View

Dewaraja Y, Frey E, Sgouros G, Brill A, Roberson P, Zanzonico P . MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med. 2012; 53(8):1310-25. PMC: 3465844. DOI: 10.2967/jnumed.111.100123. View

Gosewisch A, Delker A, Tattenberg S, Ilhan H, Todica A, Brosch J . Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA,Tyr]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach. EJNMMI Res. 2018; 8(1):76. PMC: 6081875. DOI: 10.1186/s13550-018-0427-z. View

Bolch W, Eckerman K, Sgouros G, Thomas S . MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature. J Nucl Med. 2009; 50(3):477-84. DOI: 10.2967/jnumed.108.056036. View

Glatting G, Kletting P, Reske S, Hohl K, Ring C . Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test. Med Phys. 2007; 34(11):4285-92. DOI: 10.1118/1.2794176. View

Valkema R, Pauwels S, Kvols L, Kwekkeboom D, Jamar F, de Jong M . Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005; 46 Suppl 1:83S-91S. View

10.

Prideaux A, Song H, Hobbs R, He B, Frey E, Ladenson P . Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med. 2007; 48(6):1008-16. PMC: 2974276. DOI: 10.2967/jnumed.106.038000. View

11.

Sundlov A, Sjogreen-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P . Individualised Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017; 44(9):1480-1489. PMC: 5506097. DOI: 10.1007/s00259-017-3678-4. View

12.

Sandstrom M, Ilan E, Karlberg A, Johansson S, Freedman N, Garske-Roman U . Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours. EJNMMI Phys. 2015; 2(1):24. PMC: 4883125. DOI: 10.1186/s40658-015-0127-y. View

13.

Mckay E . A software tool for specifying voxel models for dosimetry estimation. Cancer Biother Radiopharm. 2003; 18(3):379-92. DOI: 10.1089/108497803322285125. View

14.

Sohlberg A, Watabe H, Iida H . Acceleration of Monte Carlo-based scatter compensation for cardiac SPECT. Phys Med Biol. 2008; 53(14):N277-85. DOI: 10.1088/0031-9155/53/14/N02. View

15.

Pasciak A, Bourgeois A, Bradley Y . A Comparison of Techniques for (90)Y PET/CT Image-Based Dosimetry Following Radioembolization with Resin Microspheres. Front Oncol. 2014; 4:121. PMC: 4033229. DOI: 10.3389/fonc.2014.00121. View

16.

Tagesson M, Ljungberg M, Strand S . A Monte-Carlo program converting activity distributions to absorbed dose distributions in a radionuclide treatment planning system. Acta Oncol. 1996; 35(3):367-72. DOI: 10.3109/02841869609101653. View

17.

Gear J, Cox M, Gustafsson J, Sjogreen Gleisner K, Murray I, Glatting G . EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. Eur J Nucl Med Mol Imaging. 2018; 45(13):2456-2474. PMC: 6208822. DOI: 10.1007/s00259-018-4136-7. View

18.

Bailey D, Hennessy T, Willowson K, Henry E, Chan D, Aslani A . In vivo quantification of (177)Lu with planar whole-body and SPECT/CT gamma camera imaging. EJNMMI Phys. 2015; 2(1):20. PMC: 4573647. DOI: 10.1186/s40658-015-0123-2. View

19.

Zhao W, Esquinas P, Hou X, Uribe C, Gonzalez M, Beauregard J . Determination of gamma camera calibration factors for quantitation of therapeutic radioisotopes. EJNMMI Phys. 2018; 5(1):8. PMC: 5930296. DOI: 10.1186/s40658-018-0208-9. View

20.

Guy M, Flux G, Papavasileiou P, Flower M, Ott R . RMDP: a dedicated package for 131I SPECT quantification, registration and patient-specific dosimetry. Cancer Biother Radiopharm. 2003; 18(1):61-9. DOI: 10.1089/108497803321269331. View